These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 3029270)

  • 1. A synthetic peptide induces long-term protection from lethal infection with herpes simplex virus 2.
    Watari E; Dietzschold B; Szokan G; Heber-Katz E
    J Exp Med; 1987 Feb; 165(2):459-70. PubMed ID: 3029270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Helper T cells induced by an immunopurified herpes simplex virus type I (HSV-I) 115 kilodalton glycoprotein (gB) protect mice against HSV-I infection.
    Chan WL; Lukig ML; Liew FY
    J Exp Med; 1985 Oct; 162(4):1304-18. PubMed ID: 2995536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination.
    Rooney JF; Wohlenberg C; Cremer KJ; Moss B; Notkins AL
    J Virol; 1988 May; 62(5):1530-4. PubMed ID: 2833606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional T cell recognition of synthetic peptides corresponding to continuous antibody epitopes of herpes simplex virus type 1 glycoprotein D.
    Wyckoff JH; Osmand AP; Eisenberg RJ; Cohen GH; Rouse BT
    Immunobiology; 1988 May; 177(2):134-48. PubMed ID: 2456985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the role of antibody-dependent cellular cytotoxic antibody activity in murine neonatal herpes simplex virus infection with antibodies to synthetic peptides of glycoprotein D and monoclonal antibodies to glycoprotein B.
    Kohl S; Strynadka NC; Hodges RS; Pereira L
    J Clin Invest; 1990 Jul; 86(1):273-8. PubMed ID: 2164044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response.
    Bettahi I; Zhang X; Afifi RE; BenMohamed L
    Viral Immunol; 2006; 19(2):220-36. PubMed ID: 16817765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virus neutralizing activity induced by synthetic peptides of glycoprotein D of herpes simplex virus type 1, selected by their reactivity with hyperimmune sera from mice.
    Geerligs HJ; Kocken CH; Drijfhout JW; Weijer WJ; Bloemhoff W; Wilterdink JB; Welling GW; Welling-Wester S
    J Gen Virol; 1990 Aug; 71 ( Pt 8)():1767-74. PubMed ID: 2167930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.
    Wang K; Tomaras GD; Jegaskanda S; Moody MA; Liao HX; Goodman KN; Berman PW; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Haynes BF; Cohen JI
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28701403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic herpes simplex virus type 2 vaccine adjuvanted with a universal CD4 T cell helper peptide induces long-term protective immunity against lethal challenge in mice.
    Li X; Zhang S; Lei J; Zhu Y; Zhou X; Xiao J; Xiang T
    Int Immunopharmacol; 2018 Aug; 61():100-108. PubMed ID: 29857239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes.
    Wizel B; Persson J; Thörn K; Nagy E; Harandi AM
    Vaccine; 2012 Jun; 30(29):4361-8. PubMed ID: 22682292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity.
    BenMohamed L; Bertrand G; McNamara CD; Gras-Masse H; Hammer J; Wechsler SL; Nesburn AB
    J Virol; 2003 Sep; 77(17):9463-73. PubMed ID: 12915561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A detergent-soluble extract of virus-infected cells free from infectious virus protects mice from lethal herpes simplex virus infection.
    Ohashi Y; Sakaue Y; Kato S; Wada T; Sato K
    Biken J; 1980 Dec; 23(4):199-204. PubMed ID: 6266395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of in vivo depletion of immunocyte populations on herpes simplex virus glycoprotein D vaccine-induced resistance to HSV2 challenge.
    Mishkin EM; Blasiak M; Giorgio D; Ishizaka ST
    Viral Immunol; 1992; 5(2):151-61. PubMed ID: 1319710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed hypersensitivity and immune protection against herpes simplex virus: suppressor T cells that regulate the induction of delayed hypersensitivity effector T cells also regulate the induction of protective T cells.
    Schrier RD; Ishioka GY; Pizer LI; Moorhead JW
    J Immunol; 1985 May; 134(5):2889-93. PubMed ID: 2580006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human T-lymphocyte response in vitro to synthetic peptides of herpes simplex virus glycoprotein D.
    DeFreitas EC; Dietzschold B; Koprowski H
    Proc Natl Acad Sci U S A; 1985 May; 82(10):3425-9. PubMed ID: 2582411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Split T-cell tolerance in herpes simplex virus-infected mice and its implication for anti-viral immunity.
    Nash AA; Ashford NP
    Immunology; 1982 Apr; 45(4):761-7. PubMed ID: 6279490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of antiviral immunity using vaccinia virus recombinants expressing cloned genes for herpes simplex virus type 1 glycoproteins.
    Martin S; Cantin E; Rouse BT
    J Gen Virol; 1989 Jun; 70 ( Pt 6)():1359-70. PubMed ID: 2543783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protectivity of herpes simplex virus antigens: studies in mice on the adjuvant effect of PICLC and on the dependence of protection on T cell competence.
    Hilfenhaus J; Christ H; Köhler R; Moser H; Kirchner H; Levy HB
    Med Microbiol Immunol; 1981; 169(4):225-35. PubMed ID: 6268955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of immunologic resistance to herpes simplex virus 1 (HSV-1) infection.
    Rager-Zisman B; Allison AC
    J Immunol; 1976 Jan; 116(1):35-40. PubMed ID: 173758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.